- Home
- IZTC vs CLSD Comparison
IZTC vs CLSD Comparison
Compare IZTC & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IZTC
- CLSD
- Stock Information
- Founded
- IZTC 2019
- CLSD 2011
- Country
- IZTC United States
- CLSD United States
- Employees
- IZTC N/A
- CLSD N/A
- Industry
- IZTC Biotechnology: Biological Products (No Diagnostic Substances)
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- IZTC Health Care
- CLSD Health Care
- Exchange
- IZTC Nasdaq
- CLSD Nasdaq
- Market Cap
- IZTC 69.5M
- CLSD 76.6M
- IPO Year
- IZTC 2024
- CLSD 2016
- Fundamental
- Price
- IZTC $16.21
- CLSD $1.01
- Analyst Decision
- IZTC
- CLSD Strong Buy
- Analyst Count
- IZTC 0
- CLSD 6
- Target Price
- IZTC N/A
- CLSD $5.33
- AVG Volume (30 Days)
- IZTC 32.5K
- CLSD 230.0K
- Earning Date
- IZTC 01-01-0001
- CLSD 11-12-2024
- Dividend Yield
- IZTC N/A
- CLSD N/A
- EPS Growth
- IZTC N/A
- CLSD N/A
- EPS
- IZTC N/A
- CLSD N/A
- Revenue
- IZTC N/A
- CLSD $7,703,000.00
- Revenue This Year
- IZTC N/A
- CLSD N/A
- Revenue Next Year
- IZTC N/A
- CLSD $91.87
- P/E Ratio
- IZTC N/A
- CLSD N/A
- Revenue Growth
- IZTC 145.01
- CLSD 248.39
- 52 Week Low
- IZTC $8.50
- CLSD $0.92
- 52 Week High
- IZTC $19.37
- CLSD $2.12
- Technical
- Relative Strength Index (RSI)
- IZTC N/A
- CLSD 42.14
- Support Level
- IZTC N/A
- CLSD $0.99
- Resistance Level
- IZTC N/A
- CLSD $1.05
- Average True Range (ATR)
- IZTC 0.00
- CLSD 0.05
- MACD
- IZTC 0.00
- CLSD 0.00
- Stochastic Oscillator
- IZTC 0.00
- CLSD 15.38
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.